两株毛筒腔菌属真菌逆转人乳腺癌细胞多药耐药性

高水平的多药耐药性（multidrug resistance,MDR）基因在肿瘤细胞中过量表达是肿瘤细胞耐药的内在原因,是导致肿瘤化疗失败的主要原素。寻求一种抑制MDR活性的抑制剂是提升抗肿瘤药物药效的重要途径。本研究采用低浓度持续诱导方法建立人乳腺癌细胞（MCF-7）耐药细胞系,结果显示,阿霉素（ADM）、紫杉醇和顺铂对MCF-7耐药细胞系有交叉耐药性,耐药指数（resistance index,RI）分别为5.11、3.55和1.79。菌株对肿瘤细胞的逆转活性筛选表明,红棕毛筒腔菌Tubeufia rubra PF02-2和河池毛筒腔菌T. hechiensis XSL05具有逆转肿瘤细胞多药耐药性为敏感性的活性,逆转倍数（reversion fold,RF）分别为3.79和1.07。结果表明,T. rubra和T. hechiensis具有开发为MDR逆转剂的潜能。

The reversal bioactivities of multidrug resistance of MCF-7/ADM cells induced by two Tubeufia fungal strains

Overexpression of multidrug resistance (MDR) gene in tumor cells is an internal cause of drug resistance of tumor cell and is the leading cause of failure in tumor chemotherapy. Therefore, making a search for an inhibitor of MDR activity is an effective way to increase the anti-tumor drug potency. In this study, drug-resistant cell line of human breast cancer cell line (MCF-7) was established by a low-level continuous induction method. The results showed that MCF-7 drug-resistant cell line has cross-resistance to doxorubicin (ADM), paclitaxel and cisplatin with the indexes (resistance index, RI) of 5.11, 3.55 and 1.79 respectively. Screening of tumor cell MDR reversal activity showed that Tubeufia rubra PF02-2 and T. hechiensis XSL05 had MDR reversal activity with reversion folds (RF) of 3.79 and 1.07 respectively. These results indicate that T. rubra and T. hechiensis have potential to be developed as MDR inhibitors.